Invion Limited is a clinical-stage life sciences company focused on the research and development of innovative photodynamic therapy technologies for the treatment of cancer and other serious diseases. Its primary asset is the Photosoft technology platform, which leverages a proprietary photosensitiser compound used in photodynamic therapy (PDT) to target a broad range of solid tumors and skin cancers, as well as atherosclerosis and infectious diseases. Invion holds exclusive licensing and distribution rights to Photosoft across Australia, New Zealand, and key Asia-Pacific markets, excluding mainland China but including Hong Kong, Macau, Taiwan, Japan, and South Korea.

The company's main drug candidate, INV043, is under clinical development and is being evaluated for efficacy and safety in indications such as non-melanoma skin cancer, prostate cancer, and triple-negative breast cancer in collaboration with leading research institutions. Invion’s approach benefits from a portfolio of patent-protected compounds, aiming to offer both therapeutic and diagnostic solutions in oncology and related fields. Operating within the pharmaceutical sector, Invion contributes to advances in targeted cancer therapies, positioning itself as a significant player in the healthcare innovation landscape of the Asia-Pacific region.